



(11) **EP 3 571 322 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
19.07.2023 Bulletin 2023/29

(45) Date of publication and mention
of the grant of the patent:
07.06.2023 Bulletin 2023/23

(21) Application number: **18741649.0**

(22) Date of filing: **19.01.2018**

(51) International Patent Classification (IPC):
C12Q 1/6886^(2018.01) C12Q 1/68^(2018.01)

(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; C12Q 2600/106; C12Q 2600/112;
C12Q 2600/158

(86) International application number:
PCT/CA2018/050060

(87) International publication number:
WO 2018/132916 (26.07.2018 Gazette 2018/30)

(54) **MOLECULAR SUBTYPING, PROGNOSIS, AND TREATMENT OF BLADDER CANCER**

MOLEKULARE UNTERTYPISIERUNG, PROGNOSE UND BEHANDLUNG VON BLASENKREBS
SOUS-TYPAGE MOLÉCULAIRE, PRONOSTIC ET TRAITEMENT DU CANCER DE LA VESSIE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **20.01.2017 US 201762448921 P**

(43) Date of publication of application:
27.11.2019 Bulletin 2019/48

(73) Proprietors:
• **VERACYTE SD, Inc.**
San Diego, CA 92121 (US)
• **THE UNIVERSITY OF BRITISH COLUMBIA**
Vancouver, BC V6T 1Z4 (CA)

(72) Inventors:
• **DAVICIONI, Elai**
La Jolla, California 92037 (US)
• **ASHAB, Hussam Al-Deen**
North York, Ontario M2K 1E8 (CA)
• **ERHO, Nicholas**
Vancouver, British Columbia V6B 6H4 (CA)
• **BLACK, Peter**
Vancouver, British Columbia V6N 2W6 (CA)

(74) Representative: **Cabinet Becker et Associés**
25, rue Louis le Grand
75002 Paris (FR)

(56) References cited:
WO-A1-2014/085666 WO-A1-2014/085666
WO-A1-2015/073949

- **MARGARET A. KNOWLES ET AL: "Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity", NATURE REVIEWS CANCER, vol. 15, no. 1, 23 December 2014 (2014-12-23), pages 25-41, XP055269452, London ISSN: 1474-175X, DOI: 10.1038/nrc3817**
- **WOONYOUNG CHOI ET AL: "Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer", NATURE REVIEWS. UROLOGY, vol. 11, no. 7, 24 June 2014 (2014-06-24), pages 400-410, XP055269413, US ISSN: 1759-4812, DOI: 10.1038/nrurol.2014.129**
- **HA KEVIN CH ET AL: "Comparison of Affymetrix Gene Array with the Exon Array shows potential application for detection of transcript isoform variation", BMC GENOMICS, BIOMED CENTRAL, vol. 10, no. 1, 12 November 2009 (2009-11-12), page 519, XP021062207, ISSN: 1471-2164, DOI: 10.1186/1471-2164-10-519**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 571 322 B8

- DAMRAUER et al.: "Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (PNAS), vol. 111, no. 8, 25 February 2014 (2014-02-25), pages 3110-3115, XP055269416, ISSN: 0027-8424
- MCCONKEY et al.: "A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer", EUROPEAN UROLOGY, vol. 69, no. 5, May 2016 (2016-05), pages 855-862, XP029501687, ISSN: 0302-2838
- SEILER et al.: "Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy", EUROPEAN UROLOGY, vol. 72, no. 4, October 2017 (2017-10), pages 544-554, XP085198426, ISSN: 0302-2838
- CHOI et al.: "Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy", CANCER CELL, vol. 25, no. 2, 10 February 2014 (2014-02-10), pages 152-165, XP028610273, ISSN: 1535-6108
- BITON et al.: "Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes", CELL REPORTS, vol. 9, no. 4, 20 November 2014 (2014-11-20), pages 1235-1245, XP055269445, ISSN: 2211-1247
- MCCONKEY et al.: "Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer", HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA, vol. 29, no. 2, April 2015 (2015-04), pages 377-94, XP009516102, ISSN: 0889-8588, DOI: 10.1016/j.hoc.2014.11.003